140 related articles for article (PubMed ID: 10894094)
1. A novel kappa-opioid receptor agonist, TRK-820, blocks the development of physical dependence on morphine in mice.
Tsuji M; Takeda H; Matsumiya T; Nagase H; Yamazaki M; Narita M; Suzuki T
Life Sci; 2000; 66(25):PL353-8. PubMed ID: 10894094
[TBL] [Abstract][Full Text] [Related]
2. The novel kappa-opioid receptor agonist TRK-820 has no affect on the development of antinociceptive tolerance to morphine in mice.
Tsuji M; Yamazaki M; Takeda H; Matsumiya T; Nagase H; Tseng LF; Narita M; Suzuki T
Eur J Pharmacol; 2000 Apr; 394(1):91-5. PubMed ID: 10771039
[TBL] [Abstract][Full Text] [Related]
3. TRK-820, a selective kappa-opioid agonist, produces potent antinociception in cynomolgus monkeys.
Endoh T; Tajima A; Izumimoto N; Suzuki T; Saitoh A; Suzuki T; Narita M; Kamei J; Tseng LF; Mizoguchi H; Nagase H
Jpn J Pharmacol; 2001 Mar; 85(3):282-90. PubMed ID: 11325021
[TBL] [Abstract][Full Text] [Related]
4. Differential properties between TRK-820 and U-50,488H on the discriminative stimulus effects in rats.
Mori T; Nomura M; Yoshizawa K; Nagase H; Narita M; Suzuki T
Life Sci; 2004 Oct; 75(20):2473-82. PubMed ID: 15350822
[TBL] [Abstract][Full Text] [Related]
5. Effect of repeated administration of TRK-820, a kappa-opioid receptor agonist, on tolerance to its antinociceptive and sedative actions.
Suzuki T; Izumimoto N; Takezawa Y; Fujimura M; Togashi Y; Nagase H; Tanaka T; Endoh T
Brain Res; 2004 Jan; 995(2):167-75. PubMed ID: 14672806
[TBL] [Abstract][Full Text] [Related]
6. Blockade of mu-opioid receptor-mediated G-protein activation and antinociception by TRK-820 in mice.
Mizoguchi H; Hung KC; Leitermann R; Narita M; Nagase H; Suzuki T; Tseng LF
Eur J Pharmacol; 2003 Feb; 461(1):35-9. PubMed ID: 12568913
[TBL] [Abstract][Full Text] [Related]
7. Pharmacological characterization of ATPM [(-)-3-aminothiazolo[5,4-b]-N-cyclopropylmethylmorphinan hydrochloride], a novel mixed kappa-agonist and mu-agonist/-antagonist that attenuates morphine antinociceptive tolerance and heroin self-administration behavior.
Wang YJ; Tao YM; Li FY; Wang YH; Xu XJ; Chen J; Cao YL; Chi ZQ; Neumeyer JL; Zhang A; Liu JG
J Pharmacol Exp Ther; 2009 Apr; 329(1):306-13. PubMed ID: 19136637
[TBL] [Abstract][Full Text] [Related]
8. Potent antinociceptive effects of TRK-820, a novel kappa-opioid receptor agonist.
Endoh T; Matsuura H; Tajima A; Izumimoto N; Tajima C; Suzuki T; Saitoh A; Suzuki T; Narita M; Tseng L; Nagase H
Life Sci; 1999; 65(16):1685-94. PubMed ID: 10573186
[TBL] [Abstract][Full Text] [Related]
9. Comparison of pharmacological activities of three distinct kappa ligands (Salvinorin A, TRK-820 and 3FLB) on kappa opioid receptors in vitro and their antipruritic and antinociceptive activities in vivo.
Wang Y; Tang K; Inan S; Siebert D; Holzgrabe U; Lee DY; Huang P; Li JG; Cowan A; Liu-Chen LY
J Pharmacol Exp Ther; 2005 Jan; 312(1):220-30. PubMed ID: 15383632
[TBL] [Abstract][Full Text] [Related]
10. Generalization of NMDA-receptor antagonists to the discriminative stimulus effects of kappa-opioid receptor agonists U-50,488H, but not TRK-820 in rats.
Mori T; Nomura M; Yoshizawa K; Nagase H; Sawaguchi T; Narita M; Suzuki T
J Pharmacol Sci; 2006 Feb; 100(2):157-61. PubMed ID: 16474203
[TBL] [Abstract][Full Text] [Related]
11. Modulation of kappa-opioidergic systems on mecamylamine-precipitated nicotine-withdrawal aversion in rats.
Ise Y; Narita M; Nagase H; Suzuki T
Neurosci Lett; 2002 Apr; 323(2):164-6. PubMed ID: 11950518
[TBL] [Abstract][Full Text] [Related]
12. Effects of a newly synthesized kappa-opioid receptor agonist, TRK-820, on the discriminative stimulus and rewarding effects of cocaine in rats.
Mori T; Nomura M; Nagase H; Narita M; Suzuki T
Psychopharmacology (Berl); 2002 Apr; 161(1):17-22. PubMed ID: 11967626
[TBL] [Abstract][Full Text] [Related]
13. Drug design and synthesis of a novel kappa opioid receptor agonist with an oxabicyclo[2.2.2]octane skeleton and its pharmacology.
Nagase H; Watanabe A; Nemoto T; Yamaotsu N; Hayashida K; Nakajima M; Hasebe K; Nakao K; Mochizuki H; Hirono S; Fujii H
Bioorg Med Chem Lett; 2010 Jan; 20(1):121-4. PubMed ID: 19962305
[TBL] [Abstract][Full Text] [Related]
14. Suppression of acute herpetic pain-related responses by the kappa-opioid receptor agonist (-)-17-cyclopropylmethyl-3,14beta-dihydroxy-4,5alpha-epoxy-beta-[n-methyl-3-trans-3-(3-furyl) acrylamido] morphinan hydrochloride (TRK-820) in mice.
Takasaki I; Suzuki T; Sasaki A; Nakao K; Hirakata M; Okano K; Tanaka T; Nagase H; Shiraki K; Nojima H; Kuraishi Y
J Pharmacol Exp Ther; 2004 Apr; 309(1):36-41. PubMed ID: 14711930
[TBL] [Abstract][Full Text] [Related]
15. Heterologous mu-opioid receptor adaptation by repeated stimulation of kappa-opioid receptor: up-regulation of G-protein activation and antinociception.
Narita M; Khotib J; Suzuki M; Ozaki S; Yajima Y; Suzuki T
J Neurochem; 2003 Jun; 85(5):1171-9. PubMed ID: 12753076
[TBL] [Abstract][Full Text] [Related]
16. The novel kappa-opioid receptor agonist TRK-820 suppresses the rewarding and locomotor-enhancing effects of morphine in mice.
Tsuji M; Takeda H; Matsumiya T; Nagase H; Narita M; Suzuki T
Life Sci; 2001 Mar; 68(15):1717-25. PubMed ID: 11270618
[TBL] [Abstract][Full Text] [Related]
17. Mu and kappa opioid receptor agonists antagonize icilin-induced wet-dog shaking in rats.
Werkheiser JL; Rawls SM; Cowan A
Eur J Pharmacol; 2006 Oct; 547(1-3):101-5. PubMed ID: 16945367
[TBL] [Abstract][Full Text] [Related]
18. Phosphoproteomic approach for agonist-specific signaling in mouse brains: mTOR pathway is involved in κ opioid aversion.
Liu JJ; Chiu YT; DiMattio KM; Chen C; Huang P; Gentile TA; Muschamp JW; Cowan A; Mann M; Liu-Chen LY
Neuropsychopharmacology; 2019 Apr; 44(5):939-949. PubMed ID: 30082888
[TBL] [Abstract][Full Text] [Related]
19. The role of nitric oxide in the development of opioid withdrawal induced by naloxone after acute treatment with mu- and kappa-opioid receptor agonists.
Capasso A; Sorrentino L; Pinto A
Eur J Pharmacol; 1998 Oct; 359(2-3):127-31. PubMed ID: 9832382
[TBL] [Abstract][Full Text] [Related]
20. Spinal kappa-opioid system plays an important role in suppressing morphine withdrawal syndrome in the rat.
Cui CL; Wu LZ; Han JS
Neurosci Lett; 2000 Dec; 295(1-2):45-8. PubMed ID: 11078933
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
